Search hospitals

>

Florida

>

Miami

University of Miami

Claim this profile

Miami, Florida 33136

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Diabetes

Conducts research for HIV Infection

Conducts research for Lung Cancer

1134 reported clinical trials

182 medical researchers

Photo of University of Miami in Miami

Summary

University of Miami is a medical facility located in Miami, Florida. This center is recognized for care of Cancer, Breast Cancer, Diabetes, HIV Infection, Lung Cancer and other specialties. University of Miami is involved with conducting 1,134 clinical trials across 1,253 conditions. There are 182 research doctors associated with this hospital, such as Julio C Barredo, MD, Jose Lutzky, MD, Danielle Horn, and David Baidal, Dr..

Area of expertise

1

Cancer

Global Leader

University of Miami has run 53 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Breast Cancer

Global Leader

University of Miami has run 46 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 positive

Top PIs

Clinical Trials running at University of Miami

Breast Cancer

Non-Hodgkin's Lymphoma

Parkinson's Disease

Lymphoma

B-Cell Lymphoma

Multiple Myeloma

Cancer

Depression

Colorectal Cancer

Acute Myeloid Leukemia

Image of trial facility.

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Recruiting

2 awards

Phase 3

3 criteria

Image of trial facility.

Farletuzumab Ecteribulin

for Solid Cancers

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part. (divided in two parts: Part A \[OC and EC participants\] and Part B \[OC only\]): Part A: to evaluate other farletuzumab ecteribulin (MORAb-202) treatment regimens for safety, tolerability and preliminary efficacy in participants with OC and EC; to evaluate the addition of short course of oral corticosteroids following every dose of farletuzumab ecteribulin (MORAb-202) administered every 21 days; and to select treatment regimens with farletuzumab ecteribulin (MORAb-202) for further evaluation in Part B. Part B: to evaluate the safety and tolerability of different doses of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib and to determine the recommended dose (RD) of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib.

Recruiting

1 award

Phase 1 & 2

Image of trial facility.

IAM1363

for Breast Cancer

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

Recruiting

1 award

Phase 1

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Miami?

Where is University of Miami located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Miami accept?

What awards or recognition has University of Miami received?